
## Bridget K Marcellino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1720442/publications.pdf Version: 2024-02-01



| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Advances, 2018, 2, 3581-3589.   | 5.2  | 49        |
| 2  | The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.<br>Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 415-421.   | 0.4  | 38        |
| 3  | Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in<br>Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. HemaSphere, 2021, 5,<br>e549.                     | 2.7  | 29        |
| 4  | A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and<br>post-Âpolycythemia vera/essential thrombocythemia myelofibrosis (post-ÂPV/ET MF). Leukemia Research,<br>2020, 88, 106272.         | 0.8  | 25        |
| 5  | Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.<br>Blood Advances, 2020, 4, 5735-5744.   | 5.2  | 21        |
| 6  | Clinical Course of Cancer Patients With COVID-19: A Retrospective Cohort Study. JNCI Cancer<br>Spectrum, 2021, 5, pkaa085.  | 2.9  | 15        |
| 7  | Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood Reviews, 2019, 36, 23-31.   | 5.7  | 14        |
| 8  | Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clinical Advances in<br>Hematology and Oncology, 2018, 16, 619-626.   | 0.3  | 13        |
| 9  | Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19. Annals of Hematology, 2021, 100, 833-835.   | 1.8  | 11        |
| 10 | Activation of cytotoxic T cell population and inversion of CD4:CD8 ratio as manifestations of cellular immune response in SARS-COV-2 infection. Journal of Hematopathology, 2020, 13, 197-199.  | 0.4  | 8         |
| 11 | Myeloid Sarcoma of the Testis in Children: Clinicopathologic and Immunohistochemical<br>Characteristics With KMT2A (MLL) Gene Rearrangement Correlation. Applied Immunohistochemistry<br>and Molecular Morphology, 2020, 28, 501-507. | 1.2  | 7         |
| 12 | Management of advanced phase myeloproliferative neoplasms. Clinical Advances in Hematology and Oncology, 2019, 17, 405-411.   | 0.3  | 7         |
| 13 | Pharmacotherapy of Myelofibrosis. Drugs, 2017, 77, 1549-1563.   | 10.9 | 5         |
| 14 | A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature. Acta Haematologica, 2019, 142, 105-112.  | 1.4  | 5         |
| 15 | Neuroprotection by dietary restriction and the PPAR transcription complex. Translational Neuroscience, 2012, 3, .   | 1.4  | 4         |
| 16 | A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma. Case Reports in<br>Hematology, 2019, 2019, 1-4.   | 0.4  | 4         |
| 17 | Prevalence of Cytopenia in the General Population—A National Health and Nutrition Examination<br>Survey Analysis. Frontiers in Oncology, 2020, 10, 579075.  | 2.8  | 3         |
| 18 | Development of an MDM2 Degrader for Treatment of Acute Leukemias. Blood, 2021, 138, 1866-1866.  | 1.4  | 3         |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center<br>Markers in Diffuse Large B-Cell Lymphoma. Applied Immunohistochemistry and Molecular Morphology,<br>2020, 28, e63-e64. | 1.2 | 2         |
| 20 | Recent advances in prognostication and treatment of polycythemia vera. Faculty Reviews, 2021, 10, 29.  | 3.9 | 2         |
| 21 | Dietary Restriction and Glycolytic Inhibition Reduce Proteotoxicity and Extend Lifespan via NHR-49.<br>Current Neurobiology, 2018, 9, 1-7.   | 1.0 | 2         |
| 22 | Acquired amegakaryocytic thrombocytopenia as a rare cause of thrombocytopenia during pregnancy.<br>BMJ Case Reports, 2019, 12, e230361.  | 0.5 | 1         |
| 23 | Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute<br>Lymphoblastic Leukemia. Blood, 2018, 132, 5158-5158.  | 1.4 | 1         |
| 24 | Alternatives to intensive treatment in patients with AML. Clinical Advances in Hematology and Oncology, 2021, 19, 526-535.   | 0.3 | 1         |
| 25 | SLAM dunk for myelofibrosis?. Blood, 2019, 134, 789-791.   | 1.4 | 0         |
| 26 | Plasma hemoglobin in COVID-19: authors' reply. Annals of Hematology, 2021, 100, 2127-2127.   | 1.8 | 0         |